Cantargia receives Notice of Allowance from USPTO on IL1RAP in acute lymphatic leukemia

The United States Patent and Trademark Office (“USPTO”) has issued a Notice of
Allowance on Cantargia AB’s (“Cantargia”) patent application regarding IL1RAP as
a target molecule for antibody therapy of acute lymphatic leukemia (ALL).
The patent application with application number 13/390,459 which has now obtained
Notice of Allowance by the USPTO concerns the company´s method to use IL1RAP as
a target molecule for the treatment of hematological cancers. As a first step
the USPTO plans to issue a patent on IL1RAP as a target molecule for antibody
based therapy of ALL. As a subsequent step Cantargia is preparing a divisional
application to obtain granted claims on areas outside ALL. This means that the
examination will continue around the other parts of the original application, ie
other hematological forms of cancer.

The issuance of a Notice of Allowance indicates that the USPTO intends to
approve the company’s patent application. Certain administrative steps remain
before the patent is formally granted.

“Our patent portfolio is progressing and the information from USPTO gives
further validation of IL1RAP as a unique target molecule” says Göran Forsberg,
CEO of Cantargia AB. “It is a welcome notice, as USA is the biggest market for
cancer therapies.”

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com